Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD


June 24, 2021

Incretin-based agents were introduced into the diabetes treatment landscape to address postprandial glucose control. In the postprandial phase, nutrients are ingested; in response, incretins, such as glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide, are released, enhancing glucose-stimulated insulin secretion. The effects on insulin secretion last only until euglycemia is reached, ultimately minimizing risk for hypoglycemia. Thus, incretin-based therapy has become a popular choice for glycemia control because of their glycemic efficacy, ease of use, and low risk for hypoglycemia.

How familiar are you with this therapeutic approach to type 2 diabetes? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: